This clinical trial is for men and women with unresectable glioblastoma or gliosarcoma at first or second recurrence.
Currently available treatments for these disease groups are not very effective. The combination of DNX-2401 and pembrolizumab could enhance the efficacy of treatment against these aggressive brain tumors.
Participants on this trial will receive a single dose of DNX-2401 delivered intratumorally followed by sequential intravenous pembrolizumab every 3 weeks.
There is no potential for placebo on this trial. Participants will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.